ziftomenib + fludarabine + idarubicin + cytarabine + granulocyte colony-stimulating factor

This is a **combination therapy** comprised of five agents: - **Ziftomenib**, an oral small molecule menin inhibitor targeting the menin-KMT2A (MLL) interaction, developed primarily for acute myeloid leukemia (AML) with NPM1 mutations or KMT2A rearrangements. - **Fludarabine**, a purine analog antimetabolite that inhibits DNA synthesis and is used as chemotherapy in hematologic malignancies. - **Idarubicin**, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, causing DNA damage. - **Cytarabine**, a cytosine nucleoside analog that inhibits DNA synthesis, primarily used in leukemia treatment. - **Granulocyte colony-stimulating factor (G-CSF)**, a cytokine that stimulates neutrophil production to reduce the risk of infection during chemotherapy-induced neutropenia. This specific five-agent combination is experimental and intended for use in clinical trials for patients with acute myeloid leukemia, particularly those with molecular subtypes such as NPM1-mutant or KMT2A-rearranged AML. The major mechanism is to induce remission in AML by targeting leukemic blasts through multiple cytotoxic and targeted actions, while G-CSF supports hematopoietic recovery[1][3][4].

Brand names

KOMZIFTI

Other names

ziftomenib + FLAG-IDA + LDACziftomenib + FLAG-IDA + low-dose cytarabine